Kasus 1 dan 4

SL. is a 50-year-old female with metastatic pancreatic carcinoma; her

performance status is ECOG 2. She has been receiving gemcitabine with
palliative intent using the GIPGEM protocol. She returns to the clinic to see her
oncologist today (March 21). 
Her weight on February 3 was 50 kg.
Today’s weight: 46.5 kg     Height: 139 cm
Gemcitabine treatment history: Gemcitabine 1400 mg on February 3, 10, 17, 24,
March 1, 8 and 15.Lab results – March 21
 WBC 4.7
 ANC 2.7
 Hgb 108
 Platelets 257
 Creatinine 64
1. What is the patient’s current BSA, using the Mosteller equation?
2. The physician has prescribed 1400 mg IV gemcitabine to be given on
October 22. Are the dose and interval of treatment appropriate?
3. K.L.’s ANC = 0.9 and platelets = 180 on the day she is due to start Cycle
3, Week 1. How would these lab results affect the dose for Cycle 3?
4. Which of the following best describes the BC Cancer benefit status of
gemcitabine for K.L., considering her diagnosis? Would this change if
K.L. had advanced germ cell cancer?
5. Based on the protocol, how long should K.L. continue treatment?